Published in Immunity on June 01, 1994
CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol (1996) 3.39
T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity (2006) 3.02
Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest (2006) 2.73
Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med (1997) 2.47
Antiviral immune responses: triggers of or triggered by autoimmunity? Nat Rev Immunol (2009) 2.16
T-bet controls autoaggressive CD8 lymphocyte responses in type 1 diabetes. J Exp Med (2004) 1.88
Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin Microbiol Rev (2006) 1.81
How does type 1 diabetes develop?: the notion of homicide or β-cell suicide revisited. Diabetes (2011) 1.74
Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest (2004) 1.73
Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med (1997) 1.73
Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med (1996) 1.67
Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J Exp Med (1997) 1.67
Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue. J Exp Med (1998) 1.65
A viral epitope that mimics a self antigen can accelerate but not initiate autoimmune diabetes. J Clin Invest (2004) 1.51
Cure of prediabetic mice by viral infections involves lymphocyte recruitment along an IP-10 gradient. J Clin Invest (2004) 1.49
Combination therapy with an anti-IL-1β antibody and GAD65 DNA vaccine can reverse recent-onset diabetes in the RIP-GP mouse model. Diabetes (2014) 1.42
Immunoregulatory mechanisms triggered by viral infections protect from type 1 diabetes in mice. J Clin Invest (2009) 1.37
Viral trigger for type 1 diabetes: pros and cons. Diabetes (2008) 1.33
Thymic selection and adaptability of cytotoxic T lymphocyte responses in transgenic mice expressing a viral protein in the thymus. J Exp Med (1994) 1.31
Animal models of human type 1 diabetes. Nat Immunol (2009) 1.26
Transforming growth factor-beta suppresses the activation of CD8+ T-cells when naive but promotes their survival and function once antigen experienced: a two-faced impact on autoimmunity. Diabetes (2008) 1.25
DNA immunization to prevent autoimmune diabetes. J Clin Invest (1999) 1.20
CD4 T cell tolerance to human C-reactive protein, an inducible serum protein, is mediated by medullary thymic epithelium. J Exp Med (1998) 1.19
Contribution of T cell receptor affinity to overall avidity for virus-specific CD8+ T cell responses. Proc Natl Acad Sci U S A (2005) 1.16
Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection. J Exp Med (2012) 1.15
Can we learn from viruses how to prevent type 1 diabetes?: the role of viral infections in the pathogenesis of type 1 diabetes and the development of novel combination therapies. Diabetes (2009) 1.13
Sensitization to self (virus) antigen by in situ expression of murine interferon-gamma. J Clin Invest (1995) 1.11
Oral insulin treatment suppresses virus-induced antigen-specific destruction of beta cells and prevents autoimmune diabetes in transgenic mice. J Clin Invest (1996) 1.11
Mouse Models for Type 1 Diabetes. Drug Discov Today Dis Models (2009) 1.09
Intravital imaging of CTLs killing islet cells in diabetic mice. J Clin Invest (2011) 1.08
Suppression of autoimmune disease after vaccination with autoreactive T cells that express Qa-1 peptide complexes. J Clin Invest (2004) 1.08
Presented antigen from damaged pancreatic beta cells activates autoreactive T cells in virus-mediated autoimmune diabetes. J Clin Invest (2002) 1.07
RNA sensor-induced type I IFN prevents diabetes caused by a β cell-tropic virus in mice. J Clin Invest (2011) 1.04
Virus-induced diabetes in a transgenic model: role of cross-reacting viruses and quantitation of effector T cells needed to cause disease. J Virol (2000) 1.04
Activation of insulin-reactive CD8 T-cells for development of autoimmune diabetes. Diabetes (2009) 1.04
99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: triggering of autoimmune diseases by infections. Clin Exp Immunol (2010) 1.03
Profound impairment of adaptive immune responses by alkylating chemotherapy. J Immunol (2013) 1.02
Acute and chronic animal models for the evaluation of anti-diabetic agents. Cardiovasc Diabetol (2012) 1.02
Virus infections in type 1 diabetes. Cold Spring Harb Perspect Med (2012) 1.01
T cells infiltrate the brain in murine and human transmissible spongiform encephalopathies. J Virol (2003) 1.00
Virus infection, antiviral immunity, and autoimmunity. Immunol Rev (2013) 1.00
Usp18 driven enforced viral replication in dendritic cells contributes to break of immunological tolerance in autoimmune diabetes. PLoS Pathog (2013) 0.99
Protection against or triggering of Type 1 diabetes? Different roles for viral infections. Expert Rev Clin Immunol (2011) 0.99
Viral triggers for autoimmunity: is the 'glass of molecular mimicry' half full or half empty? J Autoimmun (2009) 0.98
Expression of adenoviral E3 transgenes in beta cells prevents autoimmune diabetes. Proc Natl Acad Sci U S A (1997) 0.98
Interleukin-21 receptor-mediated signals control autoreactive T cell infiltration in pancreatic islets. Immunity (2012) 0.98
Coupling of oral human or porcine insulin to the B subunit of cholera toxin (CTB) overcomes critical antigenic differences for prevention of type I diabetes. Clin Exp Immunol (2003) 0.97
Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. J Virol (1999) 0.96
Focal expression of interleukin-2 does not break unresponsiveness to "self" (viral) antigen expressed in beta cells but enhances development of autoimmune disease (diabetes) after initiation of an anti-self immune response. J Clin Invest (1995) 0.95
Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset type 1 diabetes. Mol Ther (2009) 0.95
Immunomodulatory dendritic cells require autologous serum to circumvent nonspecific immunosuppressive activity in vivo. Blood (2005) 0.89
Infection as a cause of type 1 diabetes? Curr Opin Rheumatol (2012) 0.88
Constitutive beta cell expression of IL-12 does not perturb self-tolerance but intensifies established autoimmune diabetes. J Clin Invest (2001) 0.87
Small molecule CXCR3 antagonist NIBR2130 has only a limited impact on type 1 diabetes in a virus-induced mouse model. Clin Exp Immunol (2011) 0.87
Adenovirus E3 MHC inhibitory genes but not TNF/Fas apoptotic inhibitory genes expressed in beta cells prevent autoimmune diabetes. Proc Natl Acad Sci U S A (2009) 0.86
Molecular mimicry: its evolution from concept to mechanism as a cause of autoimmune diseases. Monoclon Antib Immunodiagn Immunother (2014) 0.86
Optimal T-cell receptor affinity for inducing autoimmunity. Proc Natl Acad Sci U S A (2014) 0.85
Expression level of a pancreatic neo-antigen in beta cells determines degree of diabetes pathogenesis. J Autoimmun (2010) 0.84
In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice. J Virol (2004) 0.82
Mucosal tolerance to prevent type 1 diabetes: can the outcome be improved in humans? Rev Diabet Stud (2004) 0.81
Thymic tolerance to only one viral protein reduces lymphocytic choriomeningitis virus-induced immunopathology and increases survival in perforin-deficient mice. J Virol (1999) 0.81
A mathematical model of immune activation with a unified self-nonself concept. Front Immunol (2013) 0.80
Development of autoimmune diabetes in the absence of detectable IL-17A in a CD8-driven virally induced model. J Immunol (2011) 0.80
Case report: type 1 diabetes in monozygotic quadruplets. Eur J Hum Genet (2011) 0.80
Motifs for a deadly encounter. Nat Immunol (2012) 0.79
The p75 neurotrophin receptor is required for the major loss of sympathetic nerves from islets under autoimmune attack. Diabetes (2014) 0.79
Do viral infections protect from or enhance type 1 diabetes and how can we tell the difference? Cell Mol Immunol (2011) 0.79
Molecular anatomy and number of antigen specific CD8 T cells required to cause type 1 diabetes. PLoS Pathog (2012) 0.79
The rationale of vectored gene-fusion vaccines against cancer: evolving strategies and latest evidence. Ther Adv Vaccines (2013) 0.78
Blockade but not overexpression of the junctional adhesion molecule C influences virus-induced type 1 diabetes in mice. PLoS One (2013) 0.78
Molecular insights for optimizing T cell receptor specificity against cancer. Front Immunol (2013) 0.77
APECED: A Paradigm of Complex Interactions between Genetic Background and Susceptibility Factors. Front Immunol (2013) 0.77
Cytochrome P450 2D6 as a model antigen. Dig Dis (2010) 0.77
Anti-thymoglobulin (ATG) treatment does not reverse type 1 diabetes in the acute virally induced rat insulin promoter-lymphocytic choriomeningitis virus (RIP-LCMV) model. Clin Exp Immunol (2011) 0.77
A locally-blazed ant trail achieves efficient collective navigation despite limited information. Elife (2016) 0.76
Gut microbiota translocation to the pancreatic lymph nodes triggers NOD2 activation and contributes to T1D onset. J Exp Med (2016) 0.75
Spontaneous priming for anti-viral envelope cytotoxic T lymphocytes in mice transgenic for a murine leukaemia virus envelope gene (Fv4). Immunology (1997) 0.75
Diabetic ketoacidosis in pregnancy with a recent normal screening test. West J Med (1999) 0.75
Immunopathogenic Mechanisms of Autoimmune Hepatitis: How Much Do We Know from Animal Models? Int J Mol Sci (2016) 0.75
Antibody Neutralization of CXCL10 in Vivo Is Dependent on Binding to Free and Not Endothelial-bound Chemokine: IMPLICATIONS FOR THE DESIGN OF A NEW GENERATION OF ANTI-CHEMOKINE THERAPEUTIC ANTIBODIES. J Biol Chem (2017) 0.75
Beta-cell specific production of IL6 in conjunction with a mainly intracellular but not mainly surface viral protein causes diabetes. J Autoimmun (2014) 0.75
Progression of type 1 diabetes from the prediabetic stage is controlled by interferon-α signaling. Proc Natl Acad Sci U S A (2017) 0.75
Dual Role of CXCL10 as Conductor of Cellular Trafficking during Type 1 Diabetes. Int J Biomed Sci (2007) 0.75
Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol (1994) 15.93
Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med (1997) 12.08
Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J Exp Med (1984) 10.66
Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A (1986) 8.45
The virology and immunobiology of lymphocytic choriomeningitis virus infection. Adv Immunol (1980) 6.24
Pathogenesis of chronic disease associated with persistent lymphocytic choriomeningitis viral infection. I. Relationship of antibody production to disease in neonatally infected mice. J Exp Med (1969) 6.03
Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science (1998) 5.83
Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat Med (2001) 5.74
Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus: clearance of virus in vivo. J Virol (1984) 5.57
Molecular mimicry and autoimmune disease. Cell (1987) 5.31
Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci U S A (1984) 4.56
Genomic and biological variation among commonly used lymphocytic choriomeningitis virus strains. J Gen Virol (1983) 4.45
Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system. Nature (1986) 4.01
Lymphocytic choriomeningitis: production of antibody by "tolerant" infected mice. Science (1967) 4.01
Virus-induced immunosuppression: immune system-mediated destruction of virus-infected dendritic cells results in generalized immune suppression. J Virol (1995) 3.90
Detection of human cytomegalovirus in peripheral blood lymphocytes in a natural infection. Science (1985) 3.69
Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science (1985) 3.68
Immunosuppression and resultant viral persistence by specific viral targeting of dendritic cells. J Exp Med (2000) 3.50
CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J Virol (1996) 3.39
Monoclonal antibodies to lymphocytic choriomeningitis and pichinde viruses: generation, characterization, and cross-reactivity with other arenaviruses. Virology (1981) 3.26
Virus-lymphocyte interactions. IV. Molecular characterization of LCMV Armstrong (CTL+) small genomic segment and that of its variant, Clone 13 (CTL-). Virology (1988) 3.22
Pathogenesis of of cytomegalovirus infection. I. Activation of virus from bone marrow-derived lymphocytes by in vitro allogenic reaction. J Exp Med (1975) 3.13
Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol (1987) 2.97
Molecular definition of a major cytotoxic T-lymphocyte epitope in the glycoprotein of lymphocytic choriomeningitis virus. J Virol (1988) 2.82
Molecular analyses of a five-amino-acid cytotoxic T-lymphocyte (CTL) epitope: an immunodominant region which induces nonreciprocal CTL cross-reactivity. J Virol (1989) 2.79
Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6. Proc Natl Acad Sci U S A (1993) 2.79
Analyses of the cytotoxic T lymphocyte responses to glycoprotein and nucleoprotein components of lymphocytic choriomeningitis virus. Virology (1988) 2.76
NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J Virol (2000) 2.74
Organ-specific selection of viral variants during chronic infection. J Exp Med (1988) 2.71
Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci U S A (1996) 2.68
An essential role for type 1 interferon-gamma in terminating persistent viral infection. Virology (1995) 2.60
The antibody response of mice to murine leukemia virus in spontaneous infection: absence of classical immunologic tolerance (AKR mice-complement-fixing antibodies-lymphocytic choriomeningitis virus-immunofluorescence-glomerular deposits of antigen-antibody complexes). Proc Natl Acad Sci U S A (1972) 2.54
Molecular characterization of the genomic S RNA segment from lymphocytic choriomeningitis virus. Virology (1987) 2.53
Viral persistence in neurons explained by lack of major histocompatibility class I expression. Science (1991) 2.51
Histocompatibility-linked genetic control of disease susceptibility. Murine lymphocytic choriomeningitis virus infection. J Exp Med (1973) 2.39
Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med (1976) 2.34
Replication and persistence of measles virus in defined subpopulations of human leukocytes. J Virol (1975) 2.30
The primary structure of the lymphocytic choriomeningitis virus L gene encodes a putative RNA polymerase. Virology (1989) 2.25
Virus neutralization and virus-induced immune complex disease. Virus-antibody union resulting in immunoprotection or immunologic injury--two sides of the same coin. Prog Med Virol (1975) 2.23
CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response. J Exp Med (1996) 2.21
Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells. Scand J Immunol (1976) 2.18
The effect of induced chronic viral infections on the immunologic diseases of New Zealand mice. J Exp Med (1970) 2.16
Vaccination and protection from a lethal viral infection: identification, incorporation, and use of a cytotoxic T lymphocyte glycoprotein epitope. Virology (1990) 2.12
Molecular mimicry in virus infection: crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments. Proc Natl Acad Sci U S A (1983) 2.12
Immunohistochemical study of allergic encephalomyelitis. Am J Pathol (1968) 2.10
Immunologic injury in measles virus infection. II. Suppression of immune injury through antigenic modulation. J Exp Med (1975) 2.09
Multiple isoforms of CD46 (membrane cofactor protein) serve as receptors for measles virus. Proc Natl Acad Sci U S A (1994) 2.08
Pathogenesis of the slow disease of the central nervous system associated with WM 1504 E virus. I. Relationship of strain susceptibility and replication to disease. Am J Pathol (1977) 2.08
Immunologic injury of cultured cells infected with measles virus. I. role of IfG antibody and the alternative complement pathway. J Exp Med (1975) 2.06
Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. J Virol (1989) 2.05
Molecular analysis of the interaction of LCMV with its cellular receptor [alpha]-dystroglycan. J Cell Biol (2001) 2.03
Pathogenesis of murine cytomegalovirus infection: the macrophage as a permissive cell for cytomegalovirus infection, replication and latency. J Gen Virol (1979) 2.01
Protein structure of lymphocytic choriomeningitis virus: evidence for a cell-associated precursor of the virion glycopeptides. Virology (1979) 2.00
Tissue injury in lymphocytic choriomeningitis viral infection: virus-induced immunologically specific release of a cytotoxic factor from immune lymphoid cells. Virology (1970) 2.00
Virus-lymphocyte interaction: T cells of the helper subset are infected with lymphocytic choriomeningitis virus during persistent infection in vivo. J Virol (1987) 1.99
Interactions between viruses and lymphocytes. I. In vivo replication of lymphocytic choriomeningitis virus in mononuclear cells during both chronic and acute viral infections. J Immunol (1978) 1.95
Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues. J Virol (1986) 1.95
Localization of cytomegalovirus proteins and genome during fulminant central nervous system infection in an AIDS patient. J Neuropathol Exp Neurol (1986) 1.94
Mechanism of lymphocytic choriomeningitis virus entry into cells. Virology (1994) 1.93
Viruses disrupt functions of human lymphocytes. Effects of measles virus and influenza virus on lymphocyte-mediated killing and antibody production. J Exp Med (1984) 1.92
Human serum lyses RNA tumour viruses. Nature (1975) 1.92
Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. J Infect Dis (1987) 1.91
Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol (1995) 1.90
Antibody-induced redistribution of measles virus antigens on the cell surface. J Immunol (1974) 1.89
Virus-induced alterations in homeostasis: alteration in differentiated functions of infected cells in vivo. Science (1982) 1.88
Site-specific antibodies define a cleavage site conserved among arenavirus GP-C glycoproteins. J Virol (1987) 1.87
A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge. J Virol (1993) 1.86
Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor alpha-dystroglycan correlate with viral tropism and disease kinetics. J Virol (2001) 1.85
Characterization of lymphocytic choriomeningitis virus-binding protein(s): a candidate cellular receptor for the virus. J Virol (1992) 1.84
Active thymus derived suppressor lymphocytes in human cord blood. Nature (1977) 1.80
An HLA-C-restricted CD8+ cytotoxic T-lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag. J Virol (1991) 1.80
Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell. Nature (1979) 1.75
The S RNA segment of lymphocytic choriomeningitis virus codes for the nucleoprotein and glycoproteins 1 and 2. J Virol (1985) 1.74
Restricted expression of viral glycoprotein in cells of persistently infected mice. Nature (1982) 1.73
Clinical isolates of measles virus use CD46 as a cellular receptor. J Virol (2000) 1.72
Long-term persistent vesicular stomatitis virus and rabies virus infection of cells in vitro. J Gen Virol (1976) 1.71
Viruses perturb lymphocyte functions: selected principles characterizing virus-induced immunosuppression. Annu Rev Immunol (1987) 1.71
Neuron-specific expression of a hamster prion protein minigene in transgenic mice induces susceptibility to hamster scrapie agent. Neuron (1995) 1.71
Immune complex disease in chronic viral infections. J Exp Med (1971) 1.69
Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J Exp Med (1997) 1.67
Synthetic peptide immunoassay distinguishes HIV type 1 and HIV type 2 infections. Science (1987) 1.66
Restricted V-segment usage in T-cell receptors from cytotoxic T lymphocytes specific for a major epitope of lymphocytic choriomeningitis virus. J Virol (1990) 1.65
HIV and HCMV coinfect brain cells in patients with AIDS. Virology (1988) 1.65
Diversity of T-cell receptors in virus-specific cytotoxic T lymphocytes recognizing three distinct viral epitopes restricted by a single major histocompatibility complex molecule. J Virol (1992) 1.64
Measles virus and C3 binding sites are distinct on membrane cofactor protein (CD46). Proc Natl Acad Sci U S A (1995) 1.64
A CD4+ cytotoxic T-lymphocyte clone to a conserved epitope on human immunodeficiency virus type 1 p24: cytotoxic activity and secretion of interleukin-2 and interleukin-6. J Virol (1992) 1.63
Temperature-sensitive mutants of mouse hepatitis virus produce a high incidence of demyelination. Proc Natl Acad Sci U S A (1978) 1.63
A transgenic mouse model for measles virus infection of the brain. Proc Natl Acad Sci U S A (1997) 1.62
Infection of lymphocytes by a virus that aborts cytotoxic T lymphocyte activity and establishes persistent infection. J Exp Med (1991) 1.62
V and C proteins of measles virus function as virulence factors in vivo. Virology (2000) 1.61
Mouse hepatitis virus type 4 (JHM strains). induced fatal central nervous system disease. I. genetic control and murine neuron as the susceptible site of disease. J Exp Med (1981) 1.60
Genetic mapping of lymphocytic choriomeningitis virus pathogenicity: virulence in guinea pigs is associated with the L RNA segment. J Virol (1985) 1.60
Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. I. Generation and recognition of virus strains and H-2b mutants. J Immunol (1984) 1.59
Surface markers on human B and T-lymphocytes. IX. Two-color immunofluorescence studies on the association between ebv receptors and complement receptors on the surface of lymphoid cell lines. Int J Cancer (1976) 1.58